Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma. JAMA. 2022;327:464–77.
Article CAS PubMed Google Scholar
Joseph NS, Kaufman JL, Dhodapkar MV, Hofmeister CC, Almaula DK, Heffner LT, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38:1928–37.
Article CAS PubMed PubMed Central Google Scholar
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390:301–13.
Article CAS PubMed Google Scholar
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311–20.
Article CAS PubMed PubMed Central Google Scholar
Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132–47.
Article CAS PubMed PubMed Central Google Scholar
Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–83.
Article CAS PubMed Google Scholar
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, et al. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020;7:e456–e468.
Chakraborty R, Siddiqi R, Willson G, Gupta S, Asghar N, Husnain M, et al. Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: a meta‐analysis of randomized controlled trials. Cancer. 2022;128:2288–97.
Article CAS PubMed Google Scholar
D’Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Morè S, Corradini P, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024;143:592–6.
de Moraes Hungria VT, Peña C, Gómez-Almaguer D, Martínez-Cordero H, Schütz NP, Blunk V. Multiple myeloma in Latin America: a systematic review. eJHaem. 2024;5:867–78.
Article PubMed PubMed Central Google Scholar
Jandial A, Lad D, Jain A, Khadwal A, Singh C, Prakash G, et al. Characteristics and outcome of infectious complications after autologous hematopoietic cell transplantation in multiple myeloma patients. Transpl Infect Dis. 2023;25:e14123.
Article CAS PubMed Google Scholar
Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:1378–90.
Comments (0)